Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vaxcyte

Request full access

Developing superior and novel vaccines designed to treat some of the most common and deadly infectious diseases

San Carlos, United StatesFounded 2013Biotech & Life Sciences

About Vaxcyte

Vaxcyte is a biotechnology startup that focuses on the development of vaccines to combat bacterial infections. Their primary target is diseases such as invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. These diseases pose a significant threat to children and adults at risk worldwide. Vaxcyte's business operates in the global healthcare market, specifically in the vaccine sector.

Their business model revolves around the development and commercialization of broad-spectrum vaccines. They generate revenue through the sale of these vaccines once they have been approved for use. Their lead product, VAX-24, is a pneumococcal conjugate vaccine (PCV) that targets 24 different strains of the Streptococcus pneumoniae bacteria. This vaccine has been granted Breakthrough Therapy designation by the FDA for the prevention of invasive pneumococcal disease in adults.

Vaxcyte uses advanced chemistry and modern synthetic techniques, including their proprietary XpressCF™ cell-free protein synthesis platform, to produce these vaccines. This approach allows them to overcome the limitations of traditional cell-based vaccine methods and create vaccines capable of breaking down bacteria's complex defense mechanisms while maintaining their ability to trigger an immune response.

Following VAX-24, Vaxcyte is developing VAX-31, another PCV targeting 31 strains of the bacteria. They also have additional vaccine candidates in preclinical development for Group A Strep, periodontitis, and Shigella.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2020

Vaxcyte in the San Carlos ecosystem

Live from Dealroom

The Vaxcyte office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Abingworth
  • CTI Life Sciences
  • Longitude Capital
  • Roche Venture Fund
  • Frazier Healthcare Partners
  • Pivotal Life Sciences

Series B and later6 investors entered at this stage

Employees mapped 551 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 23 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Carlos HQ
Book a demo for the full country breakdown

Patents

Estimated portfolio value
$17M

15 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Vaxcyte on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.